169 related articles for article (PubMed ID: 37167901)
1. Comparison of anticoagulation monitoring strategies for adults supported on extracorporeal membrane oxygenation: A systematic review.
Sun J; Ma Y; Su W; Miao H; Guo Z; Chen Q; Zhang Y; Ma X; Chen S; Ding R
Heart Lung; 2023; 61():72-83. PubMed ID: 37167901
[TBL] [Abstract][Full Text] [Related]
2. The Impact and Statistical Analysis of a Multifaceted Anticoagulation Strategy in Children Supported on ECMO: Performance and Pitfalls.
Kessel AD; Kline M; Zinger M; McLaughlin D; Silver P; Sweberg TM
J Intensive Care Med; 2017 Jan; 32(1):59-67. PubMed ID: 26319579
[TBL] [Abstract][Full Text] [Related]
3. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
4. Activated Clotting Times Demonstrate Weak Correlation With Heparin Dosing in Adult Extracorporeal Membrane Oxygenation.
Hohlfelder B; Kelly D; Hoang M; Anger KE; Sylvester KW; Kaufman RM; Connors JM
Am J Ther; 2022 Jul; 29(4):e385-e393. PubMed ID: 31833874
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy.
Liu Y; Yuan Z; Han X; Song K; Xing J
Hamostaseologie; 2023 Jun; 43(3):171-178. PubMed ID: 35882351
[TBL] [Abstract][Full Text] [Related]
7. Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation.
Sulkowski JP; Preston TJ; Cooper JN; Duffy VL; Deans KJ; Chicoine LG; Minneci PC
J Extra Corpor Technol; 2014 Mar; 46(1):69-76. PubMed ID: 24779122
[TBL] [Abstract][Full Text] [Related]
8. The Heparin-Antithrombin Product: A Novel Value for Pediatric Extracorporeal Anticoagulation.
Rogerson CM; Hobson MJ
J Extra Corpor Technol; 2022 Jun; 54(2):115-122. PubMed ID: 35928336
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review.
Sklar MC; Sy E; Lequier L; Fan E; Kanji HD
Ann Am Thorac Soc; 2016 Dec; 13(12):2242-2250. PubMed ID: 27690525
[TBL] [Abstract][Full Text] [Related]
10. Bleeding, Thrombosis, and Transfusion With Two Heparin Anticoagulation Protocols in Venoarterial ECMO Patients.
Mazzeffi MA; Tanaka K; Roberts A; Rector R; Menaker J; Kon Z; Deatrick KB; Kaczorowski D; Griffith B; Herr D
J Cardiothorac Vasc Anesth; 2019 May; 33(5):1216-1220. PubMed ID: 30181084
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support.
Arnouk S; Altshuler D; Lewis TC; Merchan C; Smith DE; Toy B; Zakhary B; Papadopoulos J
ASAIO J; 2020 Mar; 66(3):300-306. PubMed ID: 31045921
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients.
Fitousis K; Klasek R; Mason PE; Masud F
Perfusion; 2017 Apr; 32(3):238-244. PubMed ID: 27837164
[TBL] [Abstract][Full Text] [Related]
13. Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation.
Figueroa Villalba CA; Brogan TV; McMullan DM; Yalon L; Jordan DI; Chandler WL
Crit Care Med; 2020 Dec; 48(12):e1179-e1184. PubMed ID: 33009103
[TBL] [Abstract][Full Text] [Related]
14. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
15. Discordance among assays for monitoring? Anticoagulation during extracorporeal life support.
Scott EJ; Rotar E; Dahl JJ; Beller JP; Money DT; Chancellor WZ; Mehaffey JH; Morisette M; Yarboro LT; Teman NR
Perfusion; 2023 Nov; 38(8):1714-1721. PubMed ID: 36167522
[TBL] [Abstract][Full Text] [Related]
16. Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial.
Aubron C; Chapalain X; Bailey M; Board J; Buhr H; Cartwright B; Dennis M; Hodgson C; Forrest P; McIlroy D; Murphy D; Murray L; Pellegrino V; Pilcher D; Sheldrake J; Tran H; Vallance S; Cooper DJ; McQuilten Z
Crit Care Explor; 2023 Nov; 5(11):e0999. PubMed ID: 37954899
[TBL] [Abstract][Full Text] [Related]
17. Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis.
Willems A; Roeleveld PP; Labarinas S; Cyrus JW; Muszynski JA; Nellis ME; Karam O
Perfusion; 2021 Jul; 36(5):501-512. PubMed ID: 32862767
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation and Transfusion Management During Neonatal and Pediatric Extracorporeal Membrane Oxygenation: A Survey of Medical Directors in the United States.
Ozment CP; Scott BL; Bembea MM; Spinella PC;
Pediatr Crit Care Med; 2021 Jun; 22(6):530-541. PubMed ID: 33750092
[TBL] [Abstract][Full Text] [Related]
19. Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation Complications.
McMichael ABV; Hornik CP; Hupp SR; Gordon SE; Ozment CP
ASAIO J; 2020 Mar; 66(3):307-313. PubMed ID: 30883406
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation.
Vo T; Bello A; Ragan M; Flanagan J; Johnson D
Am J Health Syst Pharm; 2023 May; 80(Suppl 2):S77-S83. PubMed ID: 36478046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
